Kavitha Ramchandran

2.6k total citations · 1 hit paper
71 papers, 990 citations indexed

About

Kavitha Ramchandran is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kavitha Ramchandran has authored 71 papers receiving a total of 990 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 31 papers in Public Health, Environmental and Occupational Health and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kavitha Ramchandran's work include Palliative Care and End-of-Life Issues (31 papers), Lung Cancer Treatments and Mutations (19 papers) and Cancer survivorship and care (18 papers). Kavitha Ramchandran is often cited by papers focused on Palliative Care and End-of-Life Issues (31 papers), Lung Cancer Treatments and Mutations (19 papers) and Cancer survivorship and care (18 papers). Kavitha Ramchandran collaborates with scholars based in United States, India and Australia. Kavitha Ramchandran's co-authors include Joel W. Neal, Heather A. Wakelee, Sukhmani K. Padda, Millie Das, Jyoti D. Patel, Jessica A. Hellyer, Jamie Von Roenn, Henning Stehr, Maximilian Diehn and Peter Kulesza and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Kavitha Ramchandran

64 papers receiving 980 citations

Hit Papers

Integrative Medicine for Pain Management in Oncology: Soc... 2022 2026 2023 2024 2022 40 80 120

Peers

Kavitha Ramchandran
Janise M. Roh United States
Raquel E. Reinbolt United States
Michael J. Messino United States
G. J. van Londen United States
Kristine M. Eilers United States
Matthias Weiss United States
Nadia Obi Germany
Jennifer R. Klemp United States
Janise M. Roh United States
Kavitha Ramchandran
Citations per year, relative to Kavitha Ramchandran Kavitha Ramchandran (= 1×) peers Janise M. Roh

Countries citing papers authored by Kavitha Ramchandran

Since Specialization
Citations

This map shows the geographic impact of Kavitha Ramchandran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kavitha Ramchandran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kavitha Ramchandran more than expected).

Fields of papers citing papers by Kavitha Ramchandran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kavitha Ramchandran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kavitha Ramchandran. The network helps show where Kavitha Ramchandran may publish in the future.

Co-authorship network of co-authors of Kavitha Ramchandran

This figure shows the co-authorship network connecting the top 25 collaborators of Kavitha Ramchandran. A scholar is included among the top collaborators of Kavitha Ramchandran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kavitha Ramchandran. Kavitha Ramchandran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Banwait, Mandeep K., Zofia Piotrowska, Karen Yun, et al.. (2025). Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer. Lung Cancer. 208. 108747–108747.
2.
Gensheimer, Michael F., et al.. (2025). Comparison of 1-year mortality predictions from vendor-supplied versus academic model for cancer patients. PeerJ. 13. e18958–e18958.
3.
Aredo, Jacqueline V., Heather A. Wakelee, Kavitha Ramchandran, et al.. (2024). Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC. JTO Clinical and Research Reports. 5(12). 100741–100741. 1 indexed citations
4.
Gensheimer, Michael F., Winifred Teuteberg, Manali I. Patel, et al.. (2024). Automated patient selection and care coaches to increase advance care planning for patients with cancer. JNCI Journal of the National Cancer Institute. 117(2). 296–302. 3 indexed citations
5.
Hui, Caressa, Eleanor Brown, Millie Das, et al.. (2023). Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer. 25(2). 186–189. 1 indexed citations
6.
Fong, Rebecca, Alison Callahan, Michael F. Gensheimer, et al.. (2023). Lessons Learned from a Multi-Site, Team-Based Serious Illness Care Program Implementation at an Academic Medical Center. Journal of Palliative Medicine. 27(1). 83–89. 2 indexed citations
7.
Chang, Daniel T., et al.. (2023). Study of Patient and Physician Attitudes Toward Automated Prognostic Models for Patients With Metastatic Cancer. JCO Clinical Cancer Informatics. 7(7). e2300023–e2300023. 2 indexed citations
8.
Desai, Aakash, Michael Glover, Gavin Hui, et al.. (2022). Racial Diversity and Reporting in United States Food and Drug Administration Registration Trials for Thoracic Malignancies from 2006 to 2020. Cancer Investigation. 41(1). 43–47. 1 indexed citations
10.
Hellyer, Jessica A., Rebecca M. Gardner, Kristen Cunanan, et al.. (2021). Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical Lung Cancer. 23(3). 264–272. 17 indexed citations
11.
Vukkadala, Neelaysh, et al.. (2021). End‐of‐Life Practice Patterns in Head and Neck Cancer. The Laryngoscope. 131(8). 1769–1773. 5 indexed citations
12.
Piper‐Vallillo, Andrew J., Rebecca M. Gardner, Kristen Cunanan, et al.. (2021). Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer. 23(3). e210–e221. 14 indexed citations
13.
Tan, Irena & Kavitha Ramchandran. (2020). The Role of Palliative Care in the Management of Patients with Lung Cancer. PubMed. 9(4). LMT39–LMT39. 3 indexed citations
14.
Jeong, Youngtae, Jessica A. Hellyer, Henning Stehr, et al.. (2019). Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(1). 274–281. 80 indexed citations
15.
Hellyer, Jessica A., Matthew A. Gubens, Kristen Cunanan, et al.. (2019). Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer. 137. 71–75. 11 indexed citations
16.
Verma, Manisha, Andrzej S. Kosinski, Michael L. Volk, et al.. (2019). Introducing Palliative Care within the Treatment of End-Stage Liver Disease: The Study Protocol of a Cluster Randomized Controlled Trial. Journal of Palliative Medicine. 22(1_suppl). 34–43. 42 indexed citations
17.
Wakelee, Heather A., Sukhmani K. Padda, Matthew Burns, et al.. (2015). Oral 1.01: Phase II trial of amrubicin in patients with previously treated advanced thymic malignancies. Journal of Thoracic Disease. 7(3). 101. 1 indexed citations
18.
Ramchandran, Kavitha, et al.. (2014). Hormonal Changes Under Altitude Stress. Defence Science Journal. 27(2). 99–104.
19.
Riess, Jonathan W., Seema Nagpal, Michael Iv, et al.. (2014). Prolonged Survival of Patients With Non–Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era. Clinical Lung Cancer. 15(3). 202–206. 58 indexed citations
20.
Ramchandran, Kavitha & Michelle E. Hauser. (2010). Phantom Limb Pain #212. Journal of Palliative Medicine. 13(10). 1285–1286. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026